New insights and results from the RE-LY trial

被引：0
|
作者：
不详
机构：
来源：
CARDIOVASCULAR JOURNAL OF AFRICA | 2011年 / 22卷 / 05期
关键词：
ATRIAL-FIBRILLATION; DABIGATRAN; WARFARIN;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：284 / 286
页数：2
相关论文
共 50 条
  • [41] Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation - a RE-LY Trial Analysis
    Hijazi, Ziad
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Andersson, Ulrika
    Connolly, Stuart J.
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Siegbahn, Agneta
    Yusuf, Salim
    Wallentin, Lars
    CIRCULATION, 2013, 128 (22)
  • [42] Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial
    Hijazi, Ziad
    Oldgren, Jonas
    Andersson, Ulrika
    Connolly, Stuart J.
    Eikelboom, EJohn W.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Yusuf, Salim
    Siegbahn, Agneta
    Wallentin, Lars
    AMERICAN HEART JOURNAL, 2017, 190 : 94 - 103
  • [43] Efficacy and Safety of Dabigatran vs. Warfarin in Patients With Atrial Fibrillation - Sub-Analysis in Japanese Population in RE-LY Trial
    Hori, Masatsugu
    Connolly, Stuart J.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    CIRCULATION JOURNAL, 2011, 75 (04) : 800 - 805
  • [44] Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial
    Ferreira, Jorge
    Ezekowitz, Michael D.
    Connolly, Stuart J.
    Brueckmann, Martina
    Fraessdorf, Mandy
    Reilly, Paul A.
    Yusuf, Salim
    Wallentin, Lars
    EUROPEAN JOURNAL OF HEART FAILURE, 2013, 15 (09) : 1053 - 1061
  • [45] Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy
    Eriksson, Niclas
    Wallentin, Lars
    Berglund, Lars
    Axelsson, Tomas
    Connolly, Stuart
    Eikelboom, John
    Ezekowitz, Michael
    Oldgren, Jonas
    Pare, Guillaume
    Reilly, Paul
    Siegbahn, Agneta
    Syvanen, Ann-Christine
    Wadelius, Claes
    Yusuf, Salim
    Wadelius, Mia
    PHARMACOGENOMICS, 2016, 17 (13) : 1425 - 1439
  • [46] Efficacy and Safety of Dabigatran Compared With Warfarin in Relation to Baseline Renal Function in Patients With Atrial Fibrillation A RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) Trial Analysis
    Hijazi, Ziad
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Andersson, Ulrika
    Connolly, Stuart J.
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Reilly, Paul A.
    Siegbahn, Agneta
    Yusuf, Salim
    Wallentin, Lars
    CIRCULATION, 2014, 129 (09) : 961 - 970
  • [47] The Effect of Dabigatran Plasma Concentrations and Patient Characteristics on the Frequency of Ischemic Stroke and Major Bleeding in Atrial Fibrillation Patients The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy)
    Reilly, Paul A.
    Lehr, Thorsten
    Haertter, Sebastian
    Connolly, Stuart J.
    Yusuf, Salim
    Eikelboom, John W.
    Ezekowitz, Michael D.
    Nehmiz, Gerhard
    Wang, Susan
    Wallentin, Lars
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (04) : 321 - 328
  • [48] Myocardial Ischemic Events in Patients With Atrial Fibrillation Treated With Dabigatran or Warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) Trial
    Hohnloser, Stefan H.
    Oldgren, Jonas
    Yang, Sean
    Wallentin, Lars
    Ezekowitz, Michael
    Reilly, Paul
    Eikelboom, John
    Brueckmann, Martina
    Yusuf, Salim
    Connolly, Stuart J.
    CIRCULATION, 2012, 125 (05) : 669 - 676
  • [49] Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial
    Alak, Aiman
    Hohnloser, Stefan H.
    Fraessdorf, Mandy
    Reilly, Paul
    Ezekowitz, Michael
    Healey, Jeff S.
    Brueckmann, Martina
    Yusuf, Salim
    Connolly, Stuart J.
    EUROPACE, 2019, 21 (07): : 1023 - 1038
  • [50] Oral anticoagulation for patients with atrial fibrillation in the ED: RE-LY AF registry analysis
    Pablo A. Mendoza
    William F. McIntyre
    Emilie P. Belley-Côté
    Jia Wang
    Ratika Parkash
    Clare L. Atzema
    Alexander P. Benz
    Jonas Oldgren
    Richard P. Whitlock
    Jeff S. Healey
    Journal of Thrombosis and Thrombolysis, 2022, 53 : 74 - 82
12345